A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
Public ClinicalTrials.gov record NCT04770779. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)
Study identification
- NCT ID
- NCT04770779
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Enrollment
- 258 participants
Conditions and interventions
Interventions
- Mitapivat Drug
- Placebo Matching Mitapivat Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2021
- Primary completion
- Apr 10, 2024
- Completion
- May 31, 2029
- Last update posted
- Apr 23, 2026
2021 – 2029
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Phoenix Children's Hospital | Phoenix | Arizona | 85016-7710 | — |
| San Diego Hospital, UC San Diego Health | La Jolla | California | 92093 | — |
| Children's Hospital Oakland | Oakland | California | 94609-1809 | — |
| Stanford Medicine | Palo Alto | California | 94304-1601 | — |
| Boston Children's Hospital | Boston | Massachusetts | 02115 | — |
| Children's Hospital of Michigan | Detroit | Michigan | 48201-2196 | — |
| Weill Cornell Medical Center | New York | New York | 10065-4870 | — |
| Duke University Medical Center | Durham | North Carolina | 27710-3038 | — |
| Penn Medicine - University of Pennsylvania Health System | Philadelphia | Pennsylvania | 19104 | — |
| Seattle Cancer Care Alliance, University of Washington | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04770779, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2026 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04770779 live on ClinicalTrials.gov.